Literature DB >> 2172271

Defective fasciculata zone function as the mechanism of glucocorticoid-remediable aldosteronism.

S Ulick1, C K Chan, J R Gill, M Gutkin, L Letcher, F Mantero, M I New.   

Abstract

Glucocorticoid-remediable aldosteronism is characterized by unusual sensitivity of aldosterone secretion to ACTH. Suppressibility by glucocorticoid and continued stimulability by exogenous ACTH has provided the basis for diagnosis and treatment of the disorder. A qualitative biochemical abnormality consisting of marked overproduction of the products of the cortisol C-18 oxidation pathway, 18-hydroxycortisol and 18-oxocortisol, has been examined in 10 patients with the disorder and compared to the normal C-18 oxidation products of corticosterone, aldosterone, and 18-hydroxycorticosterone. The technique, based on stable isotope dilution mass fragmentography, measured the tetrahydro urinary metabolites of aldosterone, 18-hydroxycorticosterone, and 18-oxocortisol and unmetabolized 18-hydroxycortisol. All 4 C-18 oxygenated corticosteroids were markedly elevated in the untreated state and showed rapid parallel suppression with low doses of glucocorticoid. The proportional changes in C-18 oxygenated cortisols together with aldosterone and 18-hydroxycorticosterone suggested the mechanism of a common catalytic site of a cytochrome P450 methyl oxidase serving both cortisol and corticosterone substrates. The ACTH-dependent secretion of the C-18 oxidation products of both corticosterone and cortisol in the disorder is attributed to the acquisition of methyl oxidase activity by the fasciculata zone, where there are abundant pools of these precursors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2172271     DOI: 10.1210/jcem-71-5-1151

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Cellular origin of aldosteronomas.

Authors:  A Ganguly
Journal:  Clin Investig       Date:  1992-05

2.  Glucocorticoid-suppressible hyperaldosteronism and adrenal tumors occurring in a single French pedigree.

Authors:  L Pascoe; X Jeunemaitre; M C Lebrethon; K M Curnow; C E Gomez-Sanchez; J M Gasc; J M Saez; P Corvol
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

Review 3.  DIAGNOSIS OF ENDOCRINE DISEASE: 18-Oxocortisol and 18-hydroxycortisol: is there clinical utility of these steroids?

Authors:  Jacques W M Lenders; Tracy Ann Williams; Martin Reincke; Celso E Gomez-Sanchez
Journal:  Eur J Endocrinol       Date:  2017-09-13       Impact factor: 6.664

4.  A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism.

Authors:  David S Geller; Junhui Zhang; Max V Wisgerhof; Cedric Shackleton; Michael Kashgarian; Richard P Lifton
Journal:  J Clin Endocrinol Metab       Date:  2008-05-27       Impact factor: 5.958

5.  In vitro glucocorticosteroid and mineralocorticosteroid biosynthesis in Conn's adenoma tissues.

Authors:  A Bogdan; A Auzéby; P F Plouin; Y Touitou
Journal:  J Endocrinol Invest       Date:  1993-01       Impact factor: 4.256

6.  Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2.

Authors:  L Pascoe; K M Curnow; L Slutsker; J M Connell; P W Speiser; M I New; P C White
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

Review 7.  Primary aldosteronism diagnostics: KCNJ5 mutations and hybrid steroid synthesis in aldosterone-producing adenomas.

Authors:  Juilee Rege; Adina F Turcu; William E Rainey
Journal:  Gland Surg       Date:  2020-02

Review 8.  Genetic determinants of human hypertension.

Authors:  R P Lifton
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.